FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216724966> ?p ?o ?g. }

• W3216724966 endingPage "149" @default.
• W3216724966 startingPage "139" @default.
• W3216724966 abstract "Abstract Objective We determined retention on open‐label cenobamate therapy in the clinical development program to assess the long‐term efficacy and tolerability of adjunctive cenobamate in individuals with uncontrolled focal seizures. Methods Data from two randomized, controlled cenobamate studies and one open‐label safety and pharmacokinetic study were pooled. Based on the percentage of participants remaining on treatment, retention rates were estimated using Kaplan‐Meier survival analyses. We performed two additional analyses to assess factors contributing to retention, stratifying a robust data set (through 2 years) by cenobamate modal dose and frequently used concomitant anti‐seizure medications. Cenobamate discontinuations and treatment‐emergent adverse events were summarized. Results Data from 1844 participants were pooled: 149 from a single‐dose randomized trial, 355 from a multi‐dose randomized trial, and 1340 from an open‐label safety and pharmacokinetic study. Most participants from randomized trials continued in open‐label extensions, and pooled data represent >95% of participants exposed to cenobamate. Baseline characteristics and disease and treatment histories were similar across studies. Median duration of cenobamate exposure was 34 months, with a median modal dose of 200 mg/day. Kaplan‐Meier estimates of cumulative cenobamate retention rates were 80% at 1 year and 72% at 2 years. Once participants reached the maintenance phase, retention rates were consistently high in participants receiving ≥100 mg/day cenobamate, and concomitant anti‐seizure medications did not affect long‐term retention. By 2 years, 535 (29%) had actually discontinued cenobamate; the most common reasons for discontinuation were adverse events (37.6%), withdrawal of consent (21.1%), and other (16.8%). Significance Treatment retention rates provide a proxy measure for long‐term efficacy, safety, tolerability, and adherence. The consistently high retention rates we found suggest that cenobamate may be an effective and well‐tolerated new treatment option for people with drug‐resistant focal seizures." @default.
• W3216724966 created "2021-12-06" @default.
• W3216724966 creator A5021099852 @default.
• W3216724966 creator A5025122018 @default.
• W3216724966 creator A5035657409 @default.
• W3216724966 creator A5052195171 @default.
• W3216724966 creator A5080322568 @default.
• W3216724966 creator A5085356343 @default.
• W3216724966 date "2021-11-23" @default.
• W3216724966 modified "2023-09-26" @default.
• W3216724966 title "Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program" @default.
• W3216724966 cites W1566314277 @default.
• W3216724966 cites W1572262481 @default.
• W3216724966 cites W1703571579 @default.
• W3216724966 cites W1970318744 @default.
• W3216724966 cites W1976354860 @default.
• W3216724966 cites W1986601214 @default.
• W3216724966 cites W1995505488 @default.
• W3216724966 cites W2022458589 @default.
• W3216724966 cites W2023205599 @default.
• W3216724966 cites W2024087203 @default.
• W3216724966 cites W2048674692 @default.
• W3216724966 cites W2053236663 @default.
• W3216724966 cites W2064013026 @default.
• W3216724966 cites W2083858155 @default.
• W3216724966 cites W2091074713 @default.
• W3216724966 cites W2121613199 @default.
• W3216724966 cites W2148393367 @default.
• W3216724966 cites W2148849941 @default.
• W3216724966 cites W2284224350 @default.
• W3216724966 cites W2341705713 @default.
• W3216724966 cites W2419659369 @default.
• W3216724966 cites W2625285695 @default.
• W3216724966 cites W2762538576 @default.
• W3216724966 cites W2944392111 @default.
• W3216724966 cites W2988342087 @default.
• W3216724966 cites W3017131961 @default.
• W3216724966 cites W3025465714 @default.
• W3216724966 cites W3025691036 @default.
• W3216724966 cites W3197256158 @default.
• W3216724966 cites W3216724966 @default.
• W3216724966 doi "https://doi.org/10.1111/epi.17134" @default.
• W3216724966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34813673" @default.
• W3216724966 hasPublicationYear "2021" @default.
• W3216724966 type Work @default.
• W3216724966 sameAs 3216724966 @default.
• W3216724966 citedByCount "17" @default.
• W3216724966 countsByYear W32167249662021 @default.
• W3216724966 countsByYear W32167249662022 @default.
• W3216724966 countsByYear W32167249662023 @default.
• W3216724966 crossrefType "journal-article" @default.
• W3216724966 hasAuthorship W3216724966A5021099852 @default.
• W3216724966 hasAuthorship W3216724966A5025122018 @default.
• W3216724966 hasAuthorship W3216724966A5035657409 @default.
• W3216724966 hasAuthorship W3216724966A5052195171 @default.
• W3216724966 hasAuthorship W3216724966A5080322568 @default.
• W3216724966 hasAuthorship W3216724966A5085356343 @default.
• W3216724966 hasBestOaLocation W32167249662 @default.
• W3216724966 hasConcept C126322002 @default.
• W3216724966 hasConcept C168563851 @default.
• W3216724966 hasConcept C187212893 @default.
• W3216724966 hasConcept C197934379 @default.
• W3216724966 hasConcept C2778375690 @default.
• W3216724966 hasConcept C2778715236 @default.
• W3216724966 hasConcept C2779384505 @default.
• W3216724966 hasConcept C38652104 @default.
• W3216724966 hasConcept C41008148 @default.
• W3216724966 hasConcept C535046627 @default.
• W3216724966 hasConcept C71924100 @default.
• W3216724966 hasConcept C79736992 @default.
• W3216724966 hasConceptScore W3216724966C126322002 @default.
• W3216724966 hasConceptScore W3216724966C168563851 @default.
• W3216724966 hasConceptScore W3216724966C187212893 @default.
• W3216724966 hasConceptScore W3216724966C197934379 @default.
• W3216724966 hasConceptScore W3216724966C2778375690 @default.
• W3216724966 hasConceptScore W3216724966C2778715236 @default.
• W3216724966 hasConceptScore W3216724966C2779384505 @default.
• W3216724966 hasConceptScore W3216724966C38652104 @default.
• W3216724966 hasConceptScore W3216724966C41008148 @default.
• W3216724966 hasConceptScore W3216724966C535046627 @default.
• W3216724966 hasConceptScore W3216724966C71924100 @default.
• W3216724966 hasConceptScore W3216724966C79736992 @default.
• W3216724966 hasIssue "1" @default.
• W3216724966 hasLocation W32167249661 @default.
• W3216724966 hasLocation W32167249662 @default.
• W3216724966 hasLocation W32167249663 @default.
• W3216724966 hasLocation W32167249664 @default.
• W3216724966 hasLocation W32167249665 @default.
• W3216724966 hasOpenAccess W3216724966 @default.
• W3216724966 hasPrimaryLocation W32167249661 @default.
• W3216724966 hasRelatedWork W1490515507 @default.
• W3216724966 hasRelatedWork W2037442049 @default.
• W3216724966 hasRelatedWork W2059313976 @default.
• W3216724966 hasRelatedWork W2089245388 @default.
• W3216724966 hasRelatedWork W2792428998 @default.
• W3216724966 hasRelatedWork W2896659597 @default.
• W3216724966 hasRelatedWork W2996750011 @default.
• W3216724966 hasRelatedWork W4283394029 @default.

• next